

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PFIZER INC.,
Petitioner,

v.

SANOFI-AVENTIS DEUTSCHLAND GMBH,
Patent Owner

Case IPR2019-00978
Patent No. 8,603,044 B2

**MOTION FOR JOINDER UNDER 35 U.S.C. § 315(c)
AND 37 C.F.R. §§ 42.22, 42.122(b)**

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
Submitted Electronically via the PTAB E2E System

TABLE OF CONTENTS

I. STATEMENT OF PRECISE RELIEF REQUESTED.....1

II. STATEMENT OF MATERIAL FACTS.....2

III. STATEMENT OF REASONS FOR RELIEF REQUESTED4

 A. Joinder is timely.....4

 B. Joinder is appropriate.....4

 1. Legal Standard.4

 2. Joinder Is Appropriate Because Both IPRs Present Exactly The Same
 Grounds And Substantially the Same Evidence Of Obviousness Concerning
 The Same Claims.5

 3. Joinder will not impact the existing trial schedule.6

 4. Joinder would simplify briefing and discovery.6

IV. CONCLUSION.....7

I. STATEMENT OF PRECISE RELIEF REQUESTED

Petitioner Pfizer Inc. (“Petitioner”) respectfully moves for joinder and/or consolidation of its today-filed petition for *Inter Partes* Review (“IPR”) of claims 11, 14, 15, 18, and 19 of U.S. Patent No. 8,603,044 B2 (“the ’044 patent”) with a previously instituted and currently pending IPR, captioned *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH.*, No. IPR2018-01676 (the “Mylan IPR”).

The Mylan IPR was instituted on April 2, 2019, on the same patent and the same claims as Petitioner’s Petition (the “Petition”) filed today. Further, Petitioner here asserts that the same claims are obvious over the same prior art based on substantially the same arguments presented in the Mylan IPR.

Petitioner has asked Mylan if it consents to joinder. As of the date of this motion, Petitioner and Mylan are in the process of discussing that request, and Mylan has not yet indicated whether it consents to this motion.

Joinder will not cause any delay in the resolution of the Mylan IPR. Joinder, therefore, is appropriate because it will promote the efficient and consistent resolution of the same patentability issues with respect to the ’044 patent, it will not delay the Mylan IPR trial schedule, and the parties in the Mylan IPR will not be prejudiced.

Petitioner also agrees to abide by and adopt all of the actions and proceedings in the Mylan IPR that may occur prior to the Board reaching its decision on the instant Petition and motion for joinder.

II. STATEMENT OF MATERIAL FACTS

1. Sanofi-Aventis Deutschland GmbH (“Patent Owner”) purportedly owns the ’044 patent.

2. Petitioner identifies the following previous litigation related to the ’044 patent:

- The ’044 patent was asserted in *Sanofi-Aventis U.S. LLC v. Merck Sharp & Dohme Corp.*, No. 1:16-cv-00812 (D. Del.), *Sanofi-Aventis U.S. LLC v. Eli Lilly and Co.*, No. 1:14-cv-00113 (D. Del.), *Sanofi-Aventis U.S. LLC v. Eli Lilly and Co.*, No. 1:14-cv-00884 (D. Del.), and *Sanofi-Aventis U.S. LLC, et al. v. Mylan GmbH, et al.*, No. 1:17-cv-00181 (N.D.W. Va.).

3. Petitioner is not aware of any reexamination certificates or pending prosecution concerning the ’044 patent. The following litigation or *inter partes* reviews related to the ’044 patent are pending:

- On April 2, 2019, the Board granted institution of *inter partes* review in the Mylan IPR. Mylan IPR, Paper 20.

- On April 2, 2019, the Board also granted institution of *inter partes* review in *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH*, Case IPR2018-01675.
- The '044 patent has been asserted in *Sanofi-Aventis U.S. LLC, et al. v. Mylan GmbH, et al.*, No. 2:17-cv-09105 (D.N.J.).

4. The Board instituted the Mylan IPR on two grounds: (1) Claims 11, 14, 15, 18, and 19 as obvious under 35 U.S.C. § 103(a) over Steinfeldt-Jensen; and (2) Claims 11, 14, 15, 18, and 19 as obvious under 35 U.S.C. § 103(a) over Møller and Steinfeldt-Jensen.

5. Along with its Motion for Joinder, Petitioner here has simultaneously filed a Petition for *Inter Partes* Review, No. IPR2019-00978, which argues, *inter alia*, that the same claims of the '044 patent are obvious over the same grounds and for substantially the same reasons set forth in the Mylan IPR. The Petition is also supported by the expert declaration of Charles Clemens. The opinions set forth in Mr. Clemens's declaration are nearly identical to the opinions set forth in the declaration of Mr. Karl R. Leinsing filed in the Mylan IPR (Mylan IPR Ex. 1011).

The grounds proposed in the present Petition are therefore the same grounds of unpatentability on which the Board instituted the Mylan IPR, and the Petition does not contain any additional arguments or evidence (except for reliance on a different expert, as noted above) in support of the unpatentability of claims 11, 14,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.